Cell-Penetrating Peptide PepFect14 Successfully Delivers Gene Therapy to the Nucleus of Myotonic Dystrophy Cells

Of two cell-penetrating peptides tested for delivering antisense oligonucleotides (ASOs) to myotonic dystrophy muscle cells, only PepFect14 (PF14) successfully delivered ASOs to the nucleus and corrected disease-typical abnormal splicing in a dose-dependent manner. Nona-arginine facilitated cellular uptake but failed to deliver ASOs to the nucleus. PF14 also protected ASOs from degradation. Nuclear ASO concentrations in the upper nanomolar range were required to dissolve MBNL1 protein foci — a hallmark of myotonic dystrophy type 1 (DM1).

DM1 muscle cell model treated with ASOs complexed with either nona-arginine or PepFect14 cell-penetrating peptides. Therapeutic effect measured by correction of abnormal RNA splicing. Nuclear delivery confirmed by time-lapse confocal microscopy. ASO integrity assessed by fluorescence lifetime imaging (distinguishing intact ASO from degraded fluorophore). Nuclear concentration quantified by fluorescence correlation spectroscopy combined with immunofluorescence for MBNL1 foci.

Myotonic dystrophy type 1 is the most common adult muscular dystrophy, and ASOs targeting the disease-causing RNA expansion are a leading therapeutic approach. But getting ASOs into the nucleus where they need to work is a major delivery challenge. This study shows that the right cell-penetrating peptide (PF14) can solve this problem — not just getting cargo into cells, but specifically into the nucleus. It also establishes the critical concentration threshold needed for therapeutic effect.

This study highlights a critical distinction in cell-penetrating peptide research: getting cargo into a cell is not the same as getting it to the right place within the cell. For nuclear-acting drugs like ASOs, endosomal escape and nuclear translocation are separate hurdles. PF14's success where nona-arginine failed provides concrete data for designing better CPP delivery systems. As ASO therapies expand (nusinersen for SMA, eteplirsen for DMD), understanding delivery thresholds becomes essential for dosing and efficacy optimization.

This is an in vitro cell culture study — the DM1 muscle cell model doesn't replicate the full complexity of muscle tissue in vivo. The nuclear concentration threshold (upper nanomolar) is measured in culture and may differ in living tissue where delivery barriers are more complex. PF14's performance in cell culture may not translate to systemic delivery in animals or humans.